Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,059,000 | 8,071,000 | 5,972,000 | 4,040,000 | 2,173,000 |
| Depreciation Amortization | N/A | 6,129,000 | 4,581,000 | 2,986,000 | N/A |
| Income taxes - deferred | N/A | 1,807,000 | 1,347,000 | 869,000 | N/A |
| Accounts receivable | N/A | 137,000 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | -324,000 | N/A | N/A | N/A |
| Other Working Capital | -2,209,000 | -291,000 | -2,728,000 | -2,376,000 | -2,723,000 |
| Other Operating Activity | 2,280,000 | -1,879,000 | 473,000 | 970,000 | 3,078,000 |
| Operating Cash Flow | $2,130,000 | $13,650,000 | $9,645,000 | $6,489,000 | $2,528,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 1,529,000 | -1,408,000 | -1,405,000 | 49,000 | 51,000 |
| PPE Investments | -180,000 | -1,187,000 | -748,000 | -471,000 | -234,000 |
| Net Acquisitions | -216,000 | -10,091,000 | -10,142,000 | -10,010,000 | -9,917,000 |
| Purchase Of Investment | -36,000 | -230,000 | -125,000 | -90,000 | -52,000 |
| Sale Of Investment | 224,000 | 723,000 | 467,000 | 359,000 | 242,000 |
| Purchase Sale Intangibles | -529,000 | -930,000 | -604,000 | -355,000 | -190,000 |
| Other Investing Activity | -541,000 | -989,000 | -658,000 | -403,000 | -231,000 |
| Investing Cash Flow | $780,000 | $-13,182,000 | $-12,611,000 | $-10,566,000 | $-10,141,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 2,301,000 | 2,261,000 | 3,196,000 | 2,486,000 | 3,655,000 |
| Debt Issued | N/A | 7,126,000 | 7,126,000 | 4,945,000 | 4,945,000 |
| Debt Repayment | -1,466,000 | -2,003,000 | -2,002,000 | -2,002,000 | -1,000,000 |
| Common Stock Issued | 30,000 | N/A | 846,000 | 846,000 | N/A |
| Common Stock Repurchased | -1,922,000 | -2,842,000 | -1,074,000 | -150,000 | -141,000 |
| Dividend Paid | -7,368,000 | -6,987,000 | -6,987,000 | -6,987,000 | -6,987,000 |
| Other Financing Activity | -115,000 | 237,000 | -377,000 | -310,000 | 541,000 |
| Financing Cash Flow | $-8,540,000 | $-2,208,000 | $728,000 | $-1,172,000 | $1,013,000 |
| Exchange Rate Effect | -227,000 | 286,000 | 120,000 | 54,000 | 16,000 |
| Beginning Cash Position | 9,658,000 | 11,112,000 | 11,112,000 | 11,112,000 | 11,112,000 |
| End Cash Position | 3,801,000 | 9,658,000 | 8,994,000 | 5,917,000 | 4,528,000 |
| Net Cash Flow | $-5,857,000 | $-1,454,000 | $-2,118,000 | $-5,195,000 | $-6,584,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,130,000 | 13,650,000 | 9,645,000 | 6,489,000 | 2,528,000 |
| Capital Expenditure | -246,000 | -1,275,000 | -754,000 | -475,000 | -237,000 |
| Free Cash Flow | 1,884,000 | 12,375,000 | 8,891,000 | 6,014,000 | 2,291,000 |